Literature DB >> 14607699

Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma.

Li Zhang1, Shi-Zhen Yuan.   

Abstract

OBJECTIVE: To detect the relations of c-erbB-2 oncogene protein, epidermal growth factor receptor (EGFR) and transforming growth factor-beta1 (TGF-beta1) to the progression or metastasis of pancreatic carcinoma.
METHODS: Using streptavidinbiotin complex (SABC) method, c-erbB-2 oncongene protein, we examined immunohistochemically EGFR and TGF-beta1 expressions in wax-tissue sections from 10 individuals with normal pancreas (NP), 13 patients with chronic pancreatitis (CP) and 36 patients with pancreatic ductal adenocarcinoma (PC).
RESULTS: The positive expression rates of c-cerbB-2 oncogene protein, EGFR and TGF-beta1 in the NP, CP and PC groups were 0, 0, 10%; 7.7%, 7.7%, 7.7%; and 41.7%, 50.0%, 44.4%, respectively. The positive expression rates of the three specific proteins increased more significantly in the PC group than in the NP and CP groups (P<0.05). The individual expression of c-erbB-2, EGFR and TGF-beta1 was not related to the age and sex of the patients as well as the site, size and histopathological grade of tumors (P>0.05), but to the clinical stage of tumors (P<0.01). The coexpression rate of the three proteins was 27.8% (10/36). This coexpression in the PC group was correlated with the histopathological grades and clinical stages of tumors (P<0.01).
CONCLUSION: Detection of c-erbB-2 oncogene protein, EGFR, and TGF-beta1 expressions in pancreatic tissue is helpful to judge the malignancy, progression, and metastasis of PC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14607699

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  10 in total

1.  Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Ni Wang; Rong Jiang; Jun-Yan Yang; Cui Tang; Lei Yang; Man Xu; Qi-Feng Jiang; Zhi-Min Liu
Journal:  J Mol Histol       Date:  2013-11-26       Impact factor: 2.611

2.  Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers.

Authors:  Randy S Haun; Charles M Quick; Eric R Siegel; Ilangovan Raju; Samuel G Mackintosh; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

3.  Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Janusz Strzelczyk; Adam Janiak; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2005

4.  Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.

Authors:  Amit Mahipal; Mary J Mcdonald; Agnieszka Witkiewicz; Brian I Carr
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

5.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

6.  HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma.

Authors:  Saima Sharif; Ramesh K Ramanathan; Douglas Potter; Kathleen Cieply; Alyssa M Krasinskas
Journal:  Dig Dis Sci       Date:  2008-05-08       Impact factor: 3.199

7.  Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.

Authors:  Florence Huguet; Marie Fernet; Nicole Giocanti; Vincent Favaudon; Annette K Larsen
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493

Review 8.  Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.

Authors:  R A Smith; J Tang; C Tudur-Smith; J P Neoptolemos; P Ghaneh
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

9.  FGFR4 and TGF-β1 expression in hepatocellular carcinoma: correlation with clinicopathological features and prognosis.

Authors:  Zhixin Chen; Bao Xie; Qinhua Zhu; Qinghai Xia; Songmin Jiang; Ruoyu Cao; Lihua Shi; Dansi Qi; Xiaokun Li; Lin Cai
Journal:  Int J Med Sci       Date:  2013-11-12       Impact factor: 3.738

10.  Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis.

Authors:  Radu Angelescu; Florin Burada; Cristina Angelescu; Dan Ionut Gheonea; Sevastița Iordache; Francisc Mixich; Mihai Ioana; Adrian Săftoiu
Journal:  Endosc Ultrasound       Date:  2013-04       Impact factor: 5.628

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.